Rivaroxaban
- TRADE NAME: Xarelto (Janssen)
- INDICATIONS: Prevention of venous thromboembolism in patients undergoing knee or hip replacement surgery; treatment of deep vein thrombosis and pulmonary embolism
- CLASS: Anticoagulant, Direct factor Xa inhibitor
- HALF-LIFE: 5–9 hours
Anticoagulants, Aspirin, Atazanavir, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Combined P-glycoprotein and strong CYP3A4 inhibitors and inducers, Conivaptan, Dabigatran, Darunavir, Delavirdine, Diclofenac, Efavirenz, Enoxaparin, Erythromycin, Fosamprenavir, HIV protease inhibitors, Indinavir, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Lopinavir, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Tipranavir, Voriconazole
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
Contra-indicated in patients with active pathological bleeding.
PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS and SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 01/03/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
